Y-Intercept (HK)’s Akebia Therapeutics AKBA Stock Holding History

Y-Intercept (HK)’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,434	Closed	-$59K	–	1669
2026 Q1	$59K	Buy	+42,434	New	+$58.3K	﹤0.01%	1477
2025 Q3	–	Sell	-30,657	Closed	-$112K	–	1530
2025 Q2	$112K	Buy	+30,657	New	+$84.2K	﹤0.01%	1525
2024 Q2	–	Sell	-140,925	Closed	-$258K	–	1349
2024 Q1	$258K	Buy	+140,925	New	+$225K	0.02%	1033
2022 Q3	–	Sell	-25,303	Closed	-$9K	–	934
2022 Q2	$9K	Buy	+25,303	New	+$10.6K	﹤0.01%	816

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

EWS

Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Y-Intercept (HK)'s AKBA Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 42,434 shares — an estimated $59K sold.

Y-Intercept (HK) first reported a position in AKBA in Q2 2022 and held it in 4 quarters. The position peaked at $258K in Q1 2024. 9 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Y-Intercept (HK) reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 42,434 Akebia Therapeutics shares in Q2 2026, an estimated $59K.
Y-Intercept (HK) first reported a position in Akebia Therapeutics in Q2 2022 and held it in 4 quarters.
Y-Intercept (HK)'s Akebia Therapeutics position peaked at $258K in Q1 2024.
9 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.